AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

Each of us takes about 20,000 breaths every single day—20,000 chances for the air around us to either sustain life or to ...

AstraZeneca ($AZN) said its asthma drug Fasenra failed to hit the main target in a late trial for chronic obstructive ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

The blue-chip index FTSE 100 closed 0.2% higher and the GBP/USD is up 0.1% at 1.3660. DAX index in Germany rose 0.1%, the CAC ...

As of 0726 GMT, the blue-chip index FTSE 100 rose 0.05% and the British GBP/USD slipped 0.09% against the dollar to 1.36. DAX ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

If you take prescription medications, talk to your healthcare provider ... symptoms of conditions that make breathing difficult, like asthma and chronic obstructive pulmonary disease (COPD). Coming ...

Researchers assessed whether having a severe asthma exacerbation affected patients’ ICS therapy adherence in a way that improved future exacerbation outcomes.

H1N1 caused the 2009 swine flu pandemic, H5N1 is avian influenza, and H3N2 is a subtype that has been associated with ...

A new pediatric asthma attack prediction model combines data on attack history, salivary bacteria composition, and serum inflammatory mediator levels.

The American College of Chest Physicians (CHEST) announces a critical milestone in its long-standing advocacy to ensure ...